Key TakeawaysShares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company.Intra-Cellular shareholders will get $132 per share, valuing the company at about $14.6 billion.Intra-Cellular Therapies sells one drug treating schizophrenia and bipolar I and II depression, Caplyta, and has trials ongoing for others that could treat Alzheimer's Disease and Parkinson's Disease. Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premark ...